PlumX Metrics
Embed PlumX Metrics

Veritas® bovine pericardium for immediate breast reconstruction: A xenograft alternative to acellular dermal matrix products

European Journal of Plastic Surgery, ISSN: 0930-343X, Vol: 35, Issue: 10, Page: 717-722
2012
  • 36
    Citations
  • 0
    Usage
  • 39
    Captures
  • 0
    Mentions
  • 25
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    36
  • Captures
    39
  • Social Media
    25
    • Shares, Likes & Comments
      25
      • Facebook
        25

Article Description

Background The technical advantages in utilizing human acellular dermalmatrix (ADM) products as pectoral extenders in immediate breast reconstruction with tissue expanders or implants are well documented in the medical literature. In this study, the authors examine a commonly used biologic xenograft product that has not yet been described in the medical literature for use in immediate breast reconstruction to determine whether a lower overall complication rate is identified compared to published data on ADM products. Methods A retrospective multicenter medical record review of data on 54 subjects in 93 tissue expander/implant-based, consecutive, immediate breast reconstructions from three surgeons at different institutions was performed in which Veritas® bovine pericardium was used as the biologic graft material for the pectoral extender. Results Over a 24-month period with an average of 11-month follow-up, complication rates using Veritas® in breast reconstruction for seroma formation (7.5 %), marginal skin flap necrosis (5.4 %) infection (6.5 %), and capsular contracture (0 %) were found to compare equally or favorably with statistically significant lower overall complications relative to one comparison study and lower rates of marginal skin flap necrosis relative to two comparison studies based upon previously published data from multisurgeon studies using ADM products. Conclusions Overall complications were found to be lower with Veritas® than ADM products in comparable multisurgeon studies, though this was found to be statistically significant in only one comparison study. Level of Evidence: Level II, theraputic study. © The Author(s) 2012.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know